Factor | Univariate analysis | Muitivariate analysis | ||||
---|---|---|---|---|---|---|
Patients with proven/probable IFD (n/N) | Incidence of proven/probable IFD (%) | Comparison (P value) | SE | OR (95Â % CI) | Comparison (P value) | |
Transplantation type | ||||||
 HLA-matched related (sibling) | 1/35 | 2.86 | 0.08 |  |  |  |
 Haploidentical | 5/26 | 19.23 |  | 1.77 | 2.48 (0.08–79.46) | 0.61 |
 Unrelated | 4/27 | 14.81 |  | 1.77 | 2.24 (0.07–72.11) | 0.65 |
Antithymocyte globulin | ||||||
 Yes | 9/52 | 17.31 | 0.04 | 1.68 | 2.49 (0.09–67.66) | 0.59 |
 No | 1/36 | 2.78 |  |  |  |  |
Prolonged, profound neutropenia | ||||||
 ANC > 500/mm3 | 0/1 | 0.00 | 0.23 | 1.13 | 5.90 (0.65–53.89) | 0.12 |
 ANC < 500/mm3, <10 days | 1/18 | 5.56 |  |  |  |  |
 ANC < 500/mm3, 10–14 days | 0/17 | 0.00 |  |  |  |  |
 ANC < 500/mm3, >14 days | 9/52 | 17.31 |  |  |  |  |
Liver impairment | ||||||
 Yes | 5/24 | 20.83 | 0.12 | 0.74 | 2.07 (0.49–8.79) | 0.33 |
 No | 5/64 | 7.81 |  |  |  |  |
Time of IFD prophylaxis | ||||||
 <35 days | 5/40 | 12.50 | 1.00 | 0.76 | 1.10 (0.25–4.86) | 0.90 |
 ≥35 days | 5/48 | 10.42 |  |  |  |  |
Drugs for IFD prophylaxis | ||||||
 Fluconazole/itraconazole/ | 3/27 | 11.11 | 1.00 | 0.96 | 0.87 (0.13–5.64) | 0.88 |
 Fluconazole + itraconazoleb |  |  |  |  |  |  |
 Voriconazoleb | 4/32 | 12.50 |  | 0.91 | 1.50 (0.25–8.96) | 0.66 |
 Othersa | 3/29 | 10.34 |  |  |  |  |